Vitamin D, immunity and lupus

Lupus

Volumn 17, Issue 1, 2008, Pages 6-10

  Cutolo, Maurizio ^a   Otsa, K ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b Central Hospital   (Estonia)

Author keywords

Immune response; Systemic lupus erythematosus; Vitamin D

Indexed keywords

COLECALCIFEROL; HYDROXYCHLOROQUINE; PREDNISOLONE; VITAMIN D; VITAMIN D RECEPTOR; CALCIFEDIOL; CALCITRIOL RECEPTOR; IMMUNOLOGIC FACTOR;

AUTOIMMUNE DISEASE; DENDRITIC CELL; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; VITAMIN BLOOD LEVEL; VITAMIN DEFICIENCY; ANIMAL; BLOOD; HOSPITALIZATION; IMMUNOLOGY; METABOLISM; VITAMIN D DEFICIENCY;

ANIMALS; CALCIFEDIOL; DENDRITIC CELLS; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, CALCITRIOL; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 41749115914     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307085879     Document Type: Review

References (45)

1. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutrition 2004; 6: 1678S-1688S.
2. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new etiological and therapeutical considerations. Ann Rheum Dis 2007; 66: 1137-1142.
3. Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J 2001; 15: 2579-2585.
4. Langub MC, Reinhardt TA, Horst RL. et al. Characterization of vitamin D receptor immunoreactivity in human bone cells. Bone 2000; 27: 383-387.
5. Mahon BD, Wittke A, Weaver V et al. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 2003; 89: 922-932.
6. Bhalla AK, Amento EP, Serog B et al. 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 1984; 133: 1748-1754.
7. Lemire JM. Immunomodulatory role of 1,25-dihydroxyvitamin D3. J Cell Biochem 1992; 49: 26-31.
8. Mattner F, Smiroldo S, Galbiati F et al. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur J Immunol 2000; 30: 498-508.
9. Boonstra A, Barrat FJ, Crain C et al. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001; 167: 4974-4980.
10. van EE, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93-101.
11. Cantorna MT, Woodward WD, Hayes CE et al. 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J Immunol 1998; 160: 5314-5319.
12. Staeva-Vieira TP, Freedman LP. 1,25-dihydroxyvitamin D3 inhibits IFNgamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells. J Immunol 2002; 168: 1181-1189.
13. Xue ML, Zhu H, Thakur A et al. 1 alpha,25-Dihydroxyvitamin D3 inhibits pro inflammatory cytokine and chemokine expression in human corneal epithelial cells colonized with Pseudomonas aeruginosa 5. Immunol Cell Biol 2002; 80: 340-345.
14. Stockinger B. Th17 cells: An orphan with influence 4. Immunol Cell Biol 2007; 85: 83-84.
15. Linker-Israeli M, Elstner E, Klinenberg JR et al. Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin Immunol 2001; 99: 82-93.
16. Griffin MD, Lutz W, Phan VA et al. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 6800-6805.
17. Berer A, Stockl J, Majdic O et al. 1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. Exp Hematol 2000; 28: 575-583.
18. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405-2411.
19. Griffin MD, Lutz WH, Phan VA et al. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 2000; 270: 701-708.
20. Helming L, Bose J, Ehrchen J et al. 1alpha,25-Dihydroxy vitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood 2005; 106: 4351-4358.
21. Munger KL, Zhang SM, O'Reilly E et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62: 60-65.
22. Merlino LA, Curtis J, Mikuls TR et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2004; 50: 72-77.
23. Cutolo M, Otsa K, Laas K et al. Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin Exp Rheumatol 2006; 24: 702-704.
24. Cantorna MT, Munsick C, Bemiss C et al. 1,25- Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130: 2648-2652.
25. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004; 229: 1136-1142.
26. Alarcon GS, Friedman AW, Straaton KV et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: Nature vs Nurture. Lupus 1999; 8: 197-209.
27. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006; 5: 114-117.
28. O'Regan S, Chesney RW, Hamstra A, Eisman JA, O'Gorman AM, DeLuca HF. Reduced serum 1,25-(OH)2 vitamin D3 levels in prednisone-treated adolescents with systemic lupus erythematosus. Acta Paediatr Scand 1979; 68: 109-111.
29. Huisman AM, White KP, Algra A et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol 2001; 28: 2535-2539.
30. Muller K, Kriegbaum NJ, Baslund B, Sorensen OH, Thymann M, Bentzen K. Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol 1995; 14: 397-400.
31. Abe J, Nakamura K, Takita Y, Nakano T, Irie H, Nishii Y. Prevention of immunological disorders in MRL/1 mice by a new synthetic analogue of vitamin D3: 22-oxa-1 alpha,25-dihydroxyvitamin D3. J Nutr Sci Vitaminol (Tokyo) 1990; 36: 21-31.
32. Barnes TC, Bucknall RC. Vitamin D deficiency in a patient with systemic lupus erythematosus. Rheumatology 2004; 43: 393-394.
33. Klein RG, Arnaud SB, Gallagher JC, Deluca HF, Riggs BL. Intestinal calcium absorption in exogenous hypercortisolism. Role of 25-hydroxy vitamin D and corticosteroid dose. J Clin Invest 1977; 60: 253-259.
34. Hahn TJ, Halstead LR, Haddad JG Jr. Serum 25-hydroxy vitamin D concentrations in patients receiving chronic corticosteroid therapy. J Lab Clin Med 1977; 90: 399-404.
35. Carre M, Ayigbebe O, Miravet L, Rasmussen H. The effect of prednisolone on the metabolism and action of 25-hydroxy and 1,25- dihydroxyvitamin D. Proc Natl Acad Sci USA 1974; 71: 2996-3000.
36. O'Leary TJ, Jones G, Yip A, Lohnes D, Cohanim M, Yendt ER. The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med 1986; 315: 727-730.
37. Carvalho JF, Blank M, Kiss E, Tarr T, Amital H, Shoenfeld Y. Antivitamin D, vitamin D in SLE: preliminary results. Ann N Y Acad Sci 2007; 1109: 550-557.
38. Muller K, Kriegbaum NJ, Baslund B, Sorensen OH, Thyman M, Bentzen K. Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol 1995; 14: 397-400.
39. O'Regan S, Chesney RW, Hamstra A, Eisman JA, O'Gorman AM, Deluca HF. Reduced serum 1,25-(OH)2 vitamin D3 levels in prednisolone-treated adolescents with systemic lupus erythematosus. Acta Paediatr Scand 1979; 68: 109-111.
40. Redlich K, Ziegler S, Kiener HP et al. Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Ann Rheum Dis 2000; 59: 308-310.
41. Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J 2001; 15: 2579-2585.
42. Costenbader KH, Feskanich D, Benito-Garcia E, Holmes M, Karlson E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis 2007 (Epub ahead of print).
43. Cutolo M, Otsa K, Yprus M, Seriolo B. Vitamin D and rheumatoid arthritis: comment on the letter by Nielen et al. Arthritis Rheum 2007; 56: 1719-1720.
44. Cutolo M, Maestroni GJ, Otsa K et al. Circadian melatonin and cortisol levels in rheumatoid arthritis patients in winter time: a north and south Europe comparison. Ann Rheum Dis 2005; 64: 212-216.
45. Chatfield SM, Brand C, Ebeling PR et al. Vitamin D deficiency in general medical in patients in summer and winter. Intern Med J 2007; 37: 377-382.